Implementation of Biomarker-driven Cancer Therapy: Existing Tools and Remaining Gaps

Overview

Journal Discov Med

Specialty General Medicine

Date 2014 Feb 19

PMID 24534473

Citations 29

Authors

Ann M Bailey

Yong Mao

Jia Zeng

Vijaykumar Holla

Amber Johnson

Lauren Brusco

Ken Chen

John Mendelsohn

Mark J Routbort

Gordon B Mills

Funda Meric-Bernstam

Affiliations

Soon will be listed here.

Abstract

There has been growing interest in biomarker-driven personalized cancer therapy, also known as precision medicine. Recently, dozens of molecular tests, including next generation sequencing, have been developed to detect biomarkers that have the potential to predict response of cancers to particular targeted therapies. However, detection of cancer-related biomarkers is only the first step in the battle. Deciding what therapy options to pursue can also be daunting, especially when tumors harbor more than one potentially actionable aberration. Further, different mutations/variants in a single gene may have different functional consequences, and response to targeted agents may be context dependent. However, early clinical trials with new molecular entities are increasingly conducted in a biomarker-selected fashion, and even when trials are not biomarker-selected, much effort is placed on enrolling patients onto clinical trials where they have the highest probability of response. We review available molecular tests and therapy discerning tools, including tools available for assessing functional consequences of molecular alterations and tools for finding applicable clinical trials, which exist to help bridge the gap between detection of cancer-related biomarker to the initiation of biomarker-matched targeted therapies.

Citing Articles

Two-stage stratified designs with survival outcomes and adjustment for misclassification in predictive biomarkers.

Chen Y, Lin Y, Lu S, Shih W, Quan H Stat Med. 2024; 43(10):1883-1904.

PMID: 38634277 PMC: 11068307. DOI: 10.1002/sim.10048.

Challenges and opportunities in biomarker-driven trials: adaptive randomization.

Park Y Ann Transl Med. 2022; 10(18):1035.

PMID: 36267794 PMC: 9577777. DOI: 10.21037/atm-21-6027.

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?.

Verhulst E, Garnier D, De Meester I, Bauvois B Cancers (Basel). 2022; 14(3).

PMID: 35158891 PMC: 8833564. DOI: 10.3390/cancers14030624.

Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches.

Chai J, Sugumar V, Alshanon A, Wong W, Fung S, Looi C Cancers (Basel). 2021; 13(19).

PMID: 34638233 PMC: 8507559. DOI: 10.3390/cancers13194746.

Identification of the RP11-21C4.1/SVEP1 gene pair associated with FAT2 mutations as a potential biomarker in gastric cancer.

Zhou L, Yang Y, Liu M, Gan Y, Liu R, Ren M Bioengineered. 2021; 12(1):4361-4373.

PMID: 34308747 PMC: 8806586. DOI: 10.1080/21655979.2021.1953211.

References

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

Fokkema I, Taschner P, Schaafsma G, Celli J, Laros J, den Dunnen J . LOVD v.2.0: the next generation in gene variant databases. Hum Mutat. 2011; 32(5):557-63. DOI: 10.1002/humu.21438. View

Janne P, Shaw A, Pereira J, Jeannin G, Vansteenkiste J, Barrios C . Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2012; 14(1):38-47. DOI: 10.1016/S1470-2045(12)70489-8. View

Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I . First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009; 27(9):1394-400. DOI: 10.1200/JCO.2008.18.7658. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

Jancik S, Drabek J, Radzioch D, Hajduch M . Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010; 2010:150960. PMC: 2896632. DOI: 10.1155/2010/150960. View

McDermott U, Settleman J . Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol. 2009; 27(33):5650-9. DOI: 10.1200/JCO.2009.22.9054. View

Wang Z, Gao Q, Fang J . Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer Chemother Pharmacol. 2012; 69(6):1647-55. DOI: 10.1007/s00280-012-1886-y. View

10.

De Mattos-Arruda L, Dienstmann R, Tabernero J . Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorectal Cancer. 2011; 10(4):279-89. DOI: 10.1016/j.clcc.2011.03.030. View

11.

Greaves W, Verma S, Patel K, Davies M, Barkoh B, Galbincea J . Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013; 15(2):220-6. PMC: 5707183. DOI: 10.1016/j.jmoldx.2012.10.002. View

12.

Paila U, Chapman B, Kirchner R, Quinlan A . GEMINI: integrative exploration of genetic variation and genome annotations. PLoS Comput Biol. 2013; 9(7):e1003153. PMC: 3715403. DOI: 10.1371/journal.pcbi.1003153. View

13.

Stenson P, Mort M, Ball E, Shaw K, Phillips A, Cooper D . The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2013; 133(1):1-9. PMC: 3898141. DOI: 10.1007/s00439-013-1358-4. View

14.

Mao Y, Chen H, Liang H, Meric-Bernstam F, Mills G, Chen K . CanDrA: cancer-specific driver missense mutation annotation with optimized features. PLoS One. 2013; 8(10):e77945. PMC: 3813554. DOI: 10.1371/journal.pone.0077945. View

15.

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

16.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

17.

Richardson C, Gao Q, Mitsopoulous C, Zvelebil M, Pearl L, Pearl F . MoKCa database--mutations of kinases in cancer. Nucleic Acids Res. 2008; 37(Database issue):D824-31. PMC: 2686448. DOI: 10.1093/nar/gkn832. View

18.

Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T . Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010; 120(8):2858-66. PMC: 2912177. DOI: 10.1172/JCI37539. View

19.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

20.

Sadiq A, Salgia R . MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013; 31(8):1089-96. PMC: 3589702. DOI: 10.1200/JCO.2012.43.9422. View